AcelRx's Sublingual Opioid Dsuvia Brings Unique Risk To Advisory Panel: Dropped Tablets
US FDA appears generally satisfied that AcelRx fulfilled initial safety concerns cited in October 2017 complete response letter.
US FDA appears generally satisfied that AcelRx fulfilled initial safety concerns cited in October 2017 complete response letter.